taxonomy (2)
protein (2)
source (2)
structure (0)
composition (20)
disease (1)
reference (2)
site (2)
peptide (1)
Reported structure
- HexNAc:2 (avg mass : 424.4053 )
- Hex:1 HexNAc:2 (avg mass : 586.5477 )
- Hex:2 HexNAc:2 (avg mass : 748.6901 )
- Hex:3 HexNAc:2 (avg mass : 910.8325 )
- Hex:3 HexNAc:6 (avg mass : 1723.6125 )
- Hex:4 HexNAc:2 (avg mass : 1072.9749 )
- Hex:4 HexNAc:2 dHex:1 (avg mass : 1219.1179 )
- Hex:4 HexNAc:6 (avg mass : 1885.7549 )
- Hex:4 HexNAc:6 dHex:1 (avg mass : 2031.8979 )
- Hex:5 HexNAc:2 (avg mass : 1235.1173 )
- Hex:5 HexNAc:2 dHex:1 (avg mass : 1381.2603 )
- Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
- Hex:5 HexNAc:6 (avg mass : 2047.8973 )
- Hex:6 HexNAc:2 (avg mass : 1397.2597 )
- Hex:6 HexNAc:3 (avg mass : 1600.4547 )
- Hex:6 HexNAc:3 NeuAc:1 (avg mass : 1891.7126 )
- Hex:6 HexNAc:3 dHex:1 (avg mass : 1746.5977 )
- Hex:6 HexNAc:3 dHex:2 (avg mass : 1892.7407 )
- Hex:6 HexNAc:4 NeuAc:1 (avg mass : 2094.9076 )
- Hex:7 HexNAc:2 (avg mass : 1559.4021 )
Composition
- Cancer, breast (DOID:1612)
Disease
- Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis (2019 - Nicholas M. Riley, Alexander S. Hebert, Michael S. Westphall & Joshua J. Coon ) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
Reference
- Neurocan core protein / Homo sapiens
- Neurocan core protein / Mus musculus
Reported glycosite
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
Mass spectrometry observed peptide
-
- HexNAc:2 / N-Linked (avg mass : 424.4053)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:1 HexNAc:2 / N-Linked (avg mass : 586.5477)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:2 HexNAc:2 / N-Linked (avg mass : 748.6901)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:3 HexNAc:2 / N-Linked (avg mass : 910.8325)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:4 HexNAc:2 / N-Linked (avg mass : 1072.9749)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:4 HexNAc:2 dHex:1 / N-Linked (avg mass : 1219.1179)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:5 HexNAc:2 / N-Linked (avg mass : 1235.1173)
- Cancer, breast (DOID:1612)
- Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis (2019 - Nicholas M. Riley, Alexander S. Hebert, Michael S. Westphall & Joshua J. Coon ) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Neurocan core protein / Homo sapiens
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:5 HexNAc:2 dHex:1 / N-Linked (avg mass : 1381.2603)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:2 / N-Linked (avg mass : 1397.2597)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:7 HexNAc:2 / N-Linked (avg mass : 1559.4021)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:3 / N-Linked (avg mass : 1600.4547)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:3 HexNAc:6 / N-Linked (avg mass : 1723.6125)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:3 dHex:1 / N-Linked (avg mass : 1746.5977)
- Cancer, breast (DOID:1612)
- Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis (2019 - Nicholas M. Riley, Alexander S. Hebert, Michael S. Westphall & Joshua J. Coon ) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Neurocan core protein / Homo sapiens
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:4 HexNAc:6 / N-Linked (avg mass : 1885.7549)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:3 NeuAc:1 / N-Linked (avg mass : 1891.7126)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:3 dHex:2 / N-Linked (avg mass : 1892.7407)
- Mammary Gland (UBERON_0001911)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:5 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 1932.7652)
- Brain (UBERON_0000955)
- Neurocan core protein / Mus musculus
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:4 HexNAc:6 dHex:1 / N-Linked (avg mass : 2031.8979)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:5 HexNAc:6 / N-Linked (avg mass : 2047.8973)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
-
- Hex:6 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 2094.9076)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Neurocan core protein / Homo sapiens
- ANATLLLGPLR (11aa)
- ANATLLLGPLR (11aa)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
